Latest Fibrin Stories
ROCKVILLE, Md., Jan.
SOMERVILLE, N.J., Nov. 18, 2010 /PRNewswire/ -- Ethicon, Inc., a worldwide leader in surgical care, announced today that the company has submitted a Biologic License Application (BLA) to the U.S.
ROCKVILLE, Md., Nov. 3, 2010 /PRNewswire/ -- STB Lifesaving TechnologiesÂ® today announced that it has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. government in the amount of $244,479.
ROCKVILLE, Md., Oct. 18 /PRNewswire/ -- STB Lifesaving TechnologiesÂ® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STatÂ®, or (FASTÂ®) dressing.
ROCKVILLE, Md., July 7 /PRNewswire/ -- For the third consecutive year the Department of Defense demonstrated its commitment to help save the lives of our troops by providing STB Lifesaving TechnologiesÂ® with $2.85 million of funding. The award is to further advance the development of STBÂ®'s Fibrin Adhesive STat (FASTÂ®) dressing, designed to be effective against the full spectrum of blood loss, including severe arterial and venous bleeding.
In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties.
LEIDEN, The Netherlands and SEATTLE, June 17, 2010 /PRNewswire/ -- ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that it has entered into an agreement with CSL Behring for the clinical and commercial supply of plasma-based fibrinogen and thrombin, for the manufacturing of Fibrocaps(TM). CSL Behring is a leader in the plasma protein therapeutics industry and a subsidiary of CSL Limited (ASX: CSL), a global...
New research suggests that abnormalities in the process of blood clot formation may contribute to the pathogenesis of Alzheimer's disease (AD).
Fibrin, the primary ingredient of blood clots, creates a fibrous network that stems the loss of blood at an injury site.
A joint clinical trial conducted by the University Hospital and the University of Gothenburg, Sweden, found that an element in human blood, fibrinogen, is likely more vital to the blood's clotting ability in connection with heart surgery than previously considered.